BioSpace News Archive

Nascent Biotech, Inc. is pleased to announce that its CEO, Sean Carrick, was recently interviewed by Proactive Investors ( ProactiveInvestors.com ), providing a brief history of Nascent Biotech.

Pulse Biosciences, Inc., a novel bioelectric medicine company, announced that it has commenced its previously announced rights offering of up to $15,000,000 of units at the Initial Price.

Amphera B.V. announces positive REACtiVe Phase 2 study safety and efficacy data from the first cohort of 10 patients receiving Amphera’s MesoPher dendritic cell therapy.

BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will report its financial results for the three months ended March 31, 2022 and provide a corporate update by conference call on Wednesday, May 11, 2022 at 4:30 PM ET.

SCYNEXIS, Inc. will present new data from its ongoing FURI study of ibrexafungerp during the American College of Obstetricians and Gynecologists (ACOG) Annual Clinical & Scientific Meeting being held in San Diego, May 6-8, 2022.

Gracell Biotechnologies Inc. announced that the management team will participate in and attend one-on-one meetings at three investor conferences in May 2022 as follows.

Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present at the following upcoming investor conferences.

NanoVibronix, Inc. today announced it has submitted a 510(k) application to the U.S. Food and Drug Administration (FDA) for its PainShield® MD PLUS, its dual-actuator ultrasound pain therapy device.

Xcelerate, Inc. announced that it signed a purchase agreement to acquire a portfolio of patents, patents pending and technology licenses from HS Pharmaceuticals LLC, a manufacturer and distributer of dermatological products for chronic wounds, burns and drug resistant infections.

Sagimet Biosciences, a clinical-stage biotechnology company focused on developing a portfolio of internally discovered, selective fatty acid synthase (FASN) inhibitors, announced today that it will present expanded clinical biomarker data on denifanstat (formerly known as TVB-2640), its lead product candidate for the potential treatment for nonalcoholic steatohepatitis (NASH).